Comparing The Efficacy of Different Antibiotic Regimens in The Treatment of Community-Acquired Pneumonia Based on Clinical Outcomes.
Abstract
Background: Community-acquired pneumonia is one of the most important causes for the development of morbidity and hospitalization in the world and, hence, requires timely and effective antibiotics therapy. This study was undertaken to compare the efficacy, clinical outcomes, and safety of three different antibiotic regimens in patients suffering from CAP.
Methodology: This study examined the 150 patients suffering from CAP, with fifty patients per group: Regimen A, Regimen B, and Regimen C. Important parameters observed include normalization of vital signs, clinical improvement, clinical stability, time interval to clinical improvement, length of hospital stay, side effects, mortality, and thirty-day readmission rates. Data were analyzed and tested for statistical significance to show the efficacy of the different regimens.
Results: All three regimens showed complete stability within 24 hours, with overall clinical improvement rates at 84.0%, with Regimen C showing the greatest improvement, followed by Regimen B (72.0%) and Regimen A (64.0%). This shows that although the three regimens have similar effectiveness on clinical improvement, for quicker symptom relief and clinical recovery, Regimen C emerges as the best in this study. Mean duration of hospital stay was also similar for all, ranging from 7–7.62 days, and statistically not significant (p > 0.00001). There was no death reported in any group. Side effects profile varied, with diarrhea being the most common adverse effect in Regimen C (21), whilst nausea was seen most commonly in Regimen A (20).
Conclusion: Out of all three antibiotic regimens, the choice of regimen resulted in similar efficacy in the treatment of community-acquired pneumonia, with 100% clinical stability, no mortality, and comparable lengths of stay. Regimen C had the quickest resolution of fever but higher incidence of diarrhea, whereas Regimen A demonstrated more rapid improvement in dyspnea. In general, all the regimens were effective with minimal variation in side effects and time to resolution of various other symptoms.
Downloads
References
Lüthi-Corridori G, Roth AI, Boesing M, Jaun F, Tarr PE, Leuppi-Taegtmeyer AB, Leuppi JD. Diagnosis and Therapy of Community-Acquired Pneumonia in the Emergency Department: A Retrospective Observational Study and Medical Audit. J Clin Med. 2024 Jan 19;13(2):574
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Mandell LA, Wunderink RG, Anzueto A, et al. Clin Infect Dis. 2007;44 Suppl 2:0–72.
Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care. 2011 Nov 23;1:48.
Bai AD, Srivastava S, Wong BKC, Digby GC, Razak F, Verma AA. Comparative Effectiveness of First-Line and Alternative Antibiotic Regimens in Hospitalized Patients With Nonsevere Community-Acquired Pneumonia: A Multicenter Retrospective Cohort Study. Chest. 2024 Jan;165(1):68-78.
van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005;60:672–678.
Metlay J.P. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin in Inf Dis. 2002;15:163–167.
Arulappen AL, Danial M, Ng LW, Teoh JC. The Impact of Antibiotics Administration on Mortality for Time in Sepsis and Septic Shock Patients including Possible Reasons for Delayed Administration in Malaysia. Antibiotics (Basel). 2022 Sep 5;11(9):1202.
Sharma R, Sandrock CE, Meehan J, Theriault N. Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin. Clin Drug Investig. 2020 Oct;40(10):947-960.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sathishkumar S, M. Immanuel Jebastine
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
